Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
1 . A method of treating cervical dystonia in a human subject also having a sleep disorder, the method comprising administering to the human subject a pharmaceutical composition that comprises a botulinum toxin A in an amount effective to:
a) treat the cervical dystonia in the human subject; and
b) reduce a symptom of the sleep disorder in the human subject as compared to the symptom prior to the administering;
wherein the sleep disorder is a delayed sleep phase disorder, an advanced sleep phase disorder, or a combination thereof.
2 . The method of claim 1 , wherein the human subject further has atopic disease.
3 . The method of claim 1 , wherein the human subject further suffers from a myofacial pain.
4 . The method of claim 2 , wherein the human subject further suffers from a myofacial pain.
5 . The method of claim 3 , wherein the myofacial pain is responsive to tactile stimulation.
6 . The method of claim 4 , wherein the myofacial pain is responsive to tactile stimulation.
7 . The method of claim 3 , wherein the treating results in relief from the myofacial pain.
8 . The method of claim 4 , wherein the treating results in relief from the myofacial pain.
9 . The method of claim 1 , wherein the treating prevents the cervical dystonia.
10 . The method of claim 1 , wherein the administering comprises an injection.
11 . The method of claim 10 , wherein the injection comprises at least two injection sites.
12 . The method of claim 10 , wherein the injection is multifocal.
13 . The method of claim 1 , wherein the administering is transdermal administering.
14 . The method of claim 1 , wherein the botulinum toxin A is from Hall strain Clostridium botulinum.
15 . The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
16 . The method of claim 1 , wherein the human subject is a woman.
17 . The method of claim 1 , wherein the human subject is elderly.
18 . The method of claim 16 , wherein the human subject is elderly.
19 . The method of claim 1 , wherein the sleep disorder is the delayed sleep phase disorder.
20 . The method of claim 1 , wherein the sleep disorder is the advanced sleep phase disorder.
21 . The method of claim 1 , wherein the sleep disorder is a combination of the delayed sleep phase disorder and the advanced sleep phase disorder.
22 . The method of claim 1 , wherein the human subject is a human subject in need thereof.
23 . The method of claim 20 , wherein the advanced sleep disorder comprises an age related phase advance.
24 . The method of claim 1 , wherein the human subject further comprises a pain syndrome involving a head and a neck.
25 . The method of claim 10 , wherein the botulinum toxin A is administered by injection to a neck of the human subject.
26 . The method of claim 1 , wherein the botulinum toxin A is administered in an amount of from 1.25 units to 3,000 units of the botulinum toxin A.
27 . The method of claim 1 , wherein the pharmaceutical composition further comprises a polycationic protein.
28 . The method of claim 10 , wherein the injection is a transcutaneous, a subcutaneous, a transdermal, or an intramuscular injection.
29 . The method of claim 1 , wherein the pharmaceutical composition does not contain human blood products.
30 . The method of claim 15 , wherein the pharmaceutically acceptable carrier comprises an aqueous vehicle.